City of Hope Launches Blood Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CITY OF HOPE launched an institute focused on treating blood and bone marrow diseases: the Hematologic Malignancies and Stem Cell Transplantation Institute.

The institute will be composed of six centers, individually focused on research in lymphoma, myeloma, leukemia, T cell immunotherapy, stem cell transplantation, and gene therapy. These include the Toni Stephenson Lymphoma Center and the Gehr Family Center for Leukemia Research.

The institute has recruited several prominent researchers, including Larry Kwak, chairman of the Department of Lymphoma/Myeloma at MD Anderson Cancer Center and associate director of its Center for Cancer Immunology Research; Jasmine Zain, associate director for the Bone Marrow Transplantation Program at the College of Physicians and Surgeons at the New York Presbyterian Hospital and Herbert Irving Comprehensive Cancer Center at Columbia University; John Chan, co-director of the Center for Leukemia and Lymphoma Research and co-leader of the Lymphoma Research Program at the University of Nebraska; Guido Marcucci, professor of internal medicine and molecular virology, immunology and medical genetics, and pharmaceutics in the Division of Hematology at Ohio State University Comprehensive Cancer Center; and Christiane Querfeld, dermatopathologist and lymphoma specialist at Memorial Sloan-Kettering Cancer Center.

The institute is currently launching several T cell immunotherapy clinical trials for treatment of leukemia and lymphoma, with others being developed for myeloma and transplantation.

Table of Contents

YOU MAY BE INTERESTED IN

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login